Timing note: Cencora scheduled its fiscal Q3 results and earnings call for Wednesday, August 5, 2026, before the market opens, with the call at 8:30 a.m. ET. Because August 5 is the current date, the report is scheduled for today—not tomorrow. This preview uses information available through the August 4 market close and does not incorporate the Q3 release.
Cencora enters the quarter needing to restore confidence after an unusual fiscal Q2: adjusted EPS increased and full-year EPS guidance was raised, but the company sharply reduced its revenue outlook because of manufacturer price reductions, faster brand-to-biosimilar conversions at a large mail-order customer, and slower-than-expected GLP-1 growth.
Investors treated the revenue reset as evidence that underlying growth might be slowing. The shares fell approximately 17% on May 6, the day of the Q2 report. At $306.32 on August 4, the stock had recovered roughly 21% from that selloff but remained about 18% below its March high and was effectively back near its pre-Q2-report price.
The Q3 debate is therefore less about whether reported revenue growth looks impressive and more about whether Cencora can demonstrate that:
Cencora’s fiscal Q2 guidance called for:
| Fiscal 2026 metric | Current guidance |
|---|---|
| Revenue growth | 4%–6% |
| Adjusted operating-income growth | 12%–14% |
| U.S. Healthcare Solutions operating-income growth | 14%–16% |
| International operating-income growth | 5%–8% |
| Adjusted diluted EPS | $17.65–$17.90 |
| Adjusted free cash flow | Approximately $3.0 billion |
| Net interest expense | Approximately $485 million |
| Diluted share count | Below 195.5 million |
Management also specifically forecast high-single-digit adjusted EPS growth in Q3. Against prior-year Q3 adjusted EPS of $4.00, that points to a company-implied result of roughly $4.3 per share, without relying on an unverified sell-side consensus.
Cencora generated $8.83 of adjusted EPS in the first half, leaving $8.82–$9.07 required in the second half to reach guidance. If Q3 lands around $4.3, Q4 would need to contribute approximately $4.5–$4.8.
That is demanding but consistent with management’s expectation that fiscal Q4 will be the year’s strongest growth quarter. Q4 benefits from:
Investor takeaway: A Q3 result near the implied $4.3 hurdle may be sufficient only if management firmly reiterates the full-year outlook and provides credible evidence that the expected Q4 acceleration is developing.
Fiscal Q2 revenue increased just 3.8% to $78.4 billion, and U.S. Healthcare Solutions grew 2.9%. That included several major moving parts:
Management’s argument is that the largest revenue pressures have little corresponding impact on operating income. Lower manufacturer prices can be addressed commercially, while brand sales to the affected mail-order customer carry low margins.
The market will want proof. Watch for:
A revenue miss accompanied by stable or rising operating-income guidance would support management’s “low-quality revenue” explanation. A simultaneous revenue and profit reset would be much more concerning.
The U.S. segment represents the core of the thesis. In Q2:
Management estimated that weather-related physician-office disruptions reduced Q2 operating income by $10 million and lower COVID-19 vaccine demand created another $10 million headwind. Excluding OneOncology and the lost oncology customer, management said underlying U.S. operating-income growth would have been approximately 7%, or closer to 9% before those two transitory pressures.
Q3 should no longer face the same weather disruption, but it still includes the difficult comparison associated with the lost oncology customer. That customer loss is not lapped until fiscal Q4.
The most important U.S. questions are:
Investors should be wary if management relies heavily on acquisition-driven margin expansion without quantifying organic performance.
Cencora acquired the remaining majority interest in OneOncology on February 2 for total fair-value consideration of approximately $7.4 billion, including roughly $4.65 billion in cash. Q2 contained only two months of consolidated ownership; Q3 is the first complete quarter.
The acquisition is central to Cencora’s strategy of moving further into physician-practice management and specialty pharmaceuticals. It also changes the company’s financial profile: management-service organizations carry substantially higher gross margins and operating expenses than traditional distribution.
Key items to monitor include:
OneOncology must increasingly offset the lost oncology distribution customer and the additional financing cost incurred to acquire it. A vague integration update would probably disappoint.
International Healthcare Solutions was a bright spot in Q2:
The comparison becomes favorable because prior-year Q3 international operating income declined 12.9%, largely because of weakness in global specialty logistics and consulting services.
Investors should look for a third consecutive quarter of growth at World Courier/global specialty logistics, supported by contract wins in cell and gene therapy, laboratory logistics, pricing and productivity. International results should also be assessed in constant currency because reported growth can be materially affected by exchange rates.
A sustained international rebound would add diversification to a quarter otherwise dominated by questions about the U.S. business.
Cencora ended March with:
First-half adjusted free cash flow was negative by about $1.28 billion, primarily reflecting seasonal working-capital movements. Cash generation is normally weighted toward the back of the fiscal year, but Cencora now needs more than $4 billion of second-half adjusted free cash flow to reach its annual target.
The company also said it expected to repurchase $1 billion of shares by the end of calendar 2026, after pausing buybacks to finance OneOncology. Investors should look for:
Buybacks are helpful, but aggressive repurchases alongside weak cash conversion or slower debt reduction would be less compelling.
Cencora agreed to merge MWI Animal Health with Covetrus and divested its U.S. hub consulting services. Because MWI was classified as held for sale, depreciation was suspended, creating an accounting benefit that helped raise fiscal 2026 operating-income and EPS guidance.
Investors should distinguish between:
The prior EPS guidance increase was not entirely attributable to stronger core operations.
The call will feature Eva Boratto as CFO, succeeding Jim Cleary. Investors will pay attention to her framing of the Q4 earnings ramp, acquisition returns, leverage, capital allocation and the appropriate way to measure organic growth following the addition of the MSO businesses.
Management distinguishes between two channels:
Any change in that assessment—particularly evidence that Part D conversions carry more profit than previously characterized—could materially affect the investment debate.
This would support management’s view that the Q2 selloff overreacted to revenue composition rather than a deterioration in earnings power.
The shares’ reaction would likely depend more on the credibility and specificity of Q4 guidance than on the Q3 headline numbers.
That outcome would indicate that Q2’s revenue issues were an early sign of broader operational pressure.
The central question is whether Cencora’s lower revenue growth is genuinely benign.
Management has argued that manufacturer price reductions and mail-order biosimilar conversions primarily remove low-margin revenue while specialty growth, physician-practice assets and productivity continue to support operating income. Fiscal Q3 needs to validate that argument.
The cleanest positive report would combine approximately $4.3 or better in adjusted EPS, improving core U.S. operating-income growth, visible OneOncology progress, continued international recovery and an unequivocal reiteration of the $17.65–$17.90 full-year EPS range.
Conversely, another revenue cut accompanied by weaker profit guidance would undermine the “revenue quality” thesis and make the required fiscal Q4 acceleration considerably harder to underwrite.